
July 21 (Reuters) - Johnson & Johnson JNJ.N:
JOHNSON & JOHNSON SEEKS FIRST ICOTROKINRA U.S. FDA APPROVAL AIMING TO REVOLUTIONIZE TREATMENT PARADIGM FOR ADULTS AND ADOLESCENTS WITH PLAQUE PSORIASIS
JOHNSON & JOHNSON - ICOTROKINRA MET PRIMARY ENDPOINTS IN PHASE 3 STUDIES
JOHNSON & JOHNSON - ICOTROKINRA SHOWED SUPERIORITY TO DEUCRAVACITINIB